

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Pascal DESMAZEAU, et al

Application No.: **10/790,260**

Filed: **March 02, 2004**

Title: **Streptogramin Derivatives, Preparation
Method And Compositions Containing
Same**



Examiner: **Lukton, David**

Art Unit: **1654**

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on 9-8-05

Date of Deposit

Signature

EL964825019US

Express Mail No.

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Mail Stop
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☒ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits; before the mailing of a first office action after the filing of a request for continue examination under §1.114 whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.

- ☐ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,

September 8, 2005



Balaram Gupta, Reg. No. 40,009
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3364
Telefax (908) 231-2626

Docket No. **ST98007 US CNT**

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
		Application Number	10/790,260
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	03-02-2004
		First Named Inventor	Pascal DESMAZEAU, et al
		Group Art Unit	1654
		Examiner Name	LUKTON, David
		Attorney Docket Number	ST98007 - US - CNT
Sheet	2	of	3

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ATKINSON G. et al., How To Show That Unicorn Milk Is A Chronobiotic: The Regression-to-the-Mean Statistical Artifact, Chronobiology International (2001, pp. 1041-1053, Volume 18, No. 6) Abstract Only	
		BEZEAU S. et al., Statistical Power And Effect Sizes Of Clinical Neuropsychology Research, Journal of Clinical Experimental Neuropsychology (2001, pp. 399-406, Volume 23, No. 3) Abstract Only	
		BOLTON S., Independence and Statistical Inference In Clinical Trial Designs: a Tutorial Review, Journal Clinical Pharmacology (1998, pp. 408-412, Volume 38, No. 5) Abstract Only	
		BRYANT TN, The Presentation Of Statistics, Pediatric Allergy Immunology (1998, pp. 108-115, Volume 9, No. 3) Abstract Only	
		CHUNG KC et al., The Prevalence Of Negative Studies With Inadequate Statistical Power: An Analysis Of The Plastic Surgery Literature, Plastic and Reconstructive Surgery (2002, pp. 1-6, Volume 109, No. 1) Abstract Only	
		DORIT AVRAHAMI et al., Effect of Multiple Aliphatic Amino Acids Substitutions on the Structure, Function, and Mode of Action of Diastereomeric Membrane Active Peptides, Biochemistry (2001, pp. 12591-12603, Volume 40)	
		ELISABETTA GAVINI et al., Synthesis and "in Vitro" Antimicrobial Properties of N-Oxide Derivatives Based on Tricyclic Indeno[2,1-c] pyridazine and Benzo[f] cinnoline systems, Arch. Pharm. Pharm. Med. Chem. (2000, pp.341-346, Volume 333)	
		JOHN LADBROOK, Statistics In Physiology And Pharmacology: A Slow And Erratic Learning Curve, Clinical And Experimental Pharmacology and Physiology (2001, pp. 488-492, Volume 28)	
		P. JUVVADI et al., Structure-activity studies of normal and retro pig cecropin-melittin hybrids, Journal of Peptide Research (1999, pp. 244-251, Volume 53)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/790,260
				Filing Date	03-02-2004
				First Named Inventor	DESMAZEAU
				Group Art Unit	1654
				Examiner Name	LUKTON, David
Sheet	3	of	3	Attorney Docket Number	ST98007 - US - CNT

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		RONNIE WILLENHEIMER, Statistical Significance Versus Clinical Relevance in Cardiovascular Medicine, Progress in Cardiovascular Diseases (2001, pp. 155-167, Volume 44, No. 3)	
		RYOSUKE FUDOU et al., Haliangicin, a Novel Antifungal Metabolite Produced by a Marine Myxobacterium, The Journal of Antibiotics (2001, pp. 149-152, Volume 54, No. 2)	
		VERONIQUE BLANC et al., Cloning and Analysis of Structural Genes from Streptomyces pristinaespiralis Encoding Enzymes Involved in the Conversion of Pristinamycin II beta to Pristinamycin II a (PIIA): PIIA Synthase And NADH: Riboflavin 5'-Phosphate Oxidoreductase, Journal of Bacteriology (1995, pp. 5206-5214)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.